FDA approves Allergan's newest hyaluronic acid injectable — with a new delivery system
FDA gave the green light to Allergan Aesthetics’ new delivery method for hyaluronic acid on Monday — opening up a new route of administering prescription beauty products.
The AbbVie subsidiary is branding the intradermal microdroplet injection as Skinvive by Juvéderm. The injectable contains a small amount of lidocaine, a topical anesthetic.
Juvéderm already has several other injectable hyaluronic acid formulations in its portfolio, working as dermal fillers for different parts of the face such as chin, lips, or the jawline, according to its website. The new product is indicated for skin smoothness in the cheeks for adults ages 21 and older.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.